Gastric Cancer Risk Diagnosis and Prevention in Subjects with Helicobacter pylori-related Chronic Gastritis.

This book is a comprehensive overview of invited contributions on Helicobacter pylori infection in gastritis and gastric carcinogenesis. The first part of the book covers topics related to the pathophysiology of gastric mucosal defense system and gastritis including the gastroprotective function of the mucus, the capsaicin-sensitive afferent nerves and the oxidative stress pathway involved in inflammation, apoptosis and autophagy in H. pylori related gastritis. The next chapters deal with molecular pathogenesis and treatment, which consider the role of neuroendocrine cells in gastric disease, DNA methylation in H. pylori infection, the role of antioxidants and phytotherapy in gastric disease. The final part presents the effects of cancer risk factors associated with H. pylori infection. These chapters discuss the serum pepsinogen test, K-ras mutations, cell kinetics, and H. pylori lipopolysaccharide, as well as the roles of several bacterial genes (cagA, cagT, vacA and dupA) as virulence factors in gastric cancer, and the gastrokine-1 protein in cancer progression.

This book provides essential insights into the various pathogeneses, diagnoses and therapies for patients with gastric cancer. Special attention is given to trending topics: endoscopic diagnosis, cancer screening and eradication of H. pylori as prevention of the disease. A dedicated section focuses on risk classification and cancer screening/diagnosis, and is intended for practical use in clinical doctors’ day-to-day management of patients. Since cancer screening and prevention is currently only practiced in Japan, this book is intended to disseminate new findings and serve as a point of departure for further research. Abundant color illustrations of the enhanced endoscopic imaging are also included, making it a valuable resource for GI medical doctors, medical students and those seeking detailed information on H. pylori.​

Gastric Cancer Risk Diagnosis Using Molecular Biological and Serological Markers Based on Helicobacter pylori-Related Chronic Gastritis.

- Provides in-depth, clinical reviews on Gastric Cancer, providing actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews. - Provides in-depth, clinical reviews on Gastric Cancer, providing actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

The overall prognosis for patients with gastric cancer remains poor as tumors are often diagnosed at an advanced stage, despite new developments and technical advances in endoscopic diagnosis and therapy. This publication brings together leading experts in the fields of basic research and clinical management of gastric cancer, to share their expertise with the clinical community. State-of-the-art reviews discuss the pathogenesis of and the most important risk factors for the development of gastric cancer, potential benefits of chemoprevention and Helicobacter pylori eradication. Moreover, new diagnostic modalities and surgical therapy, including the potential benefits of neoadjuvant and adjuvant therapies, are presented. As most patients require palliative therapy because of locally advanced or metastasized cancers, several reviews are dedicated to advances in the chemotherapy of advanced gastric cancers and peritoneal metastasis. Finally, future approaches towards a molecular diagnosis and therapy are described. Those involved in the management of gastric cancer patients will find the information presented in this publication of utmost help and will benefit greatly for their daily routine.

Gastric cancer is the second most common cause of cancer mortality worldwide. Although the incidence of gastric cancer has declined over the past century in the United States, it remains one of the most common gastrointestinal neoplasms, particularly in immigrants and the socio-economically deprived. Recent years have seen major advances in our understanding of the pathogenesis of gastric cancer (especially regarding the importance of Helicobacter pylori and its associated inflammatory response) and the emergence of adjuvant oncologic therapies of proven benefit for advanced cases, in addition to surgery. As for gastric adenocarcinoma, elucidation of the underlying biology and molecular pathogenesis has led to much progress in the management of two other malignant gastric neoplasms, gastrointestinal stromal tumors and marginal zone B-cell (“MALT ) lymphomas. This monograph highlights these developments, presenting an updated overview of gastric cancer that will be of interest to all practicing gastroenterologists.

Gastritis, as a medical term, exists for the last 150 years, however, terminology and etiology (including the prognosis ) has changed. Gastritis related medical problems are in the focus of different sub-disciplines: internists , gastroenterologists, pathologists, immunologists, bacteriologists, genetics, biologists etc. After the publications by Marshall and Warren most of the clinicians accepted only the etiopathological role of Helicobacter pylori in the development of gastric and duodenal ulcer , as well as in the gastric cancer. This book presents chapters abou the history of gastritis terminology, animal models, epidemiology, new gastric mucosal endogenous defensive neural mechanism (capsaicin-sinsitive afferentation), different research and clinical methods applied to the background studies and the molecular pathology, biochemistry and genetics involved in the pathways from Helicobacter pylori infection to development of gastric cancer. Intended audience of this book are internists, gastroenterologists, pathologists, bacteriologists, pharmacologists, genetics, biologists , immunologists and other interested researchers.

Stomach cancer (also called gastric cancer) is the growth of cancer cells in the lining and wall of the stomach. Stomach cancer represents roughly 2 percent (25,500) cases of all new cancer cases yearly in the United States, but it is much more common in Japan, Great Britain, South America, and Iceland. It is associated with high salt in the diet, smoking, and low intake of fruits and vegetables.Infection with H. pylori is the main risk factor in about 80 percent or more of gastric cancers. It is more common in men. A very small percentage of diffuse-type gastric cancers are thought to be genetic. Hereditary Diffuse Gastric Cancer (HDGC) has only recently been identified and research is ongoing, but genetic testing and treatment options are available for families at risk. Metastasis occurs in 80-90 percent of individuals with stomach cancer, with a five year survival rate of 75 percent in those diagnosed in early stages and less than 30 percent of those diagnosed in late stages. This book presents new and important research from around the world.